D. Perez-Zsolt

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

Beta-Cyclodextrins as affordable antivirals to treat coronavirus infection

The paper identifies beta-cyclodextrins as effective and affordable antivirals against SARS-CoV-2 and other coronaviruses through molecular modeling and in vitro testing.

Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis

This study uses electron microscopy to show plitidepsin blocks SARS-CoV-2 replication organelles and virus morphogenesis.

SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

This study shows Siglec-1 on APCs mediates SARS-CoV-2 trans-infection and triggers proinflammatory responses, suggesting it as a potential therapeutic target.

Cetylpyridinium chloride-containing mouthwashes reduce the infectivity of SARS-CoV-2 variants in vitro

This study shows that CPC-containing mouthwashes significantly reduce SARS-CoV-2 infectivity in vitro across variants by disrupting the viral envelope and inhibiting fusion.

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.